TRIAL DATA
Mitomycin C HIPEC after cytoreductive surgery shows unclear oncologic benefit in colorectal peritoneal metastasesA propensity score-matched analysis compared patients who received mitomycin C-based hyperthermic intraperitoneal chemotherapy after complete cytoreductive surgery (2009–2021) with those undergoing surgery alone (2021–2024), following the PRODIGE7 trial's finding that oxaliplatin-based HIPEC lacked effectiveness. (Ann Surg Oncol)